Compare Citius Pharmaceuticals Inc (CTXR) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Gold Fields Limited — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Gold Fields Limited trades at $40.6 (market cap $36.07B). The key difference: Gold Fields Limited is far larger — about 1802.6× Citius Pharmaceuticals Inc's market cap, and Gold Fields Limited pays a 5.76% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | GFI | |
|---|---|---|
Market Cap | $20.01M | $36.07B |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $61.52 |
52-Week Low | $0.48 | $29.31 |
Enterprise Value | $16.23M | $37.51B |
Dividend Yield | — | 5.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.
Gold Fields (GFI) trades at $41.06, down slightly by 0.15% today. The stock shows strong fundamentals with robust profitability (40.76% net margin, 52.33% ROE) and attractive valuation (P/E 10.22, EV/EBITDA 5.92). Recent earnings were mixed with one beat and two misses, but 2025 projections indicate significant growth. Technical indicators show a bullish overall signal despite overbought RSI readings. Institutional interest remains strong with recent acquisitions by major funds.
The outlook for GFI appears positive with projected revenue growth to $8.8B and net income of $3.6B in 2025. Analyst consensus targets $52.00 (24% upside) with no sell ratings. Key risks include gold price volatility and operational challenges in mining operations. The combination of strong fundamentals, institutional support, and growth projections supports a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
